Specifications table {#s0005}
====================

TableSubject area*Medicine*More specific subject area*Clinical study data*Type of data*Figures, tables, and text*How data was acquired*The data were acquired in a clinical study*Data format*Figures, tables, and text*Experimental factors*Observational clinical diagnostic study in ICD patients*Experimental features*CONSORT graph, correlation scatterplot of shock score vs. mortality score, calculation formulae for both scores, univariate Cox regression for both endpoints*Data source location*Göttingen/Germany; Leuven/Belgium; Utrecht/The Netherlands; Athens/Greece*Data accessibilityData is available in this articleRelated research articleBergau L, Willems R, Sprenkeler DJ, Fischer TH, Flevari P, Hasenfuss G, et al. Differential multivariable risk prediction of appropriate shock versus competing mortality -- a prospective cohort study to estimate benefits from ICD therapy Int J Cardiol. 2018; 272:102--7 [@bib1].

Value of the data {#s0010}
=================

•The CONSORT graph data of the prospective clinical study is shown, giving insight into the distribution of patient subjects in the study.•The correlation scatter plot data for calculated risk score values of appropriate shock vs. calculated risk score value for mortality is shown, original pairs of score values can be discerned in the graphics and are shared as a file.•The univariate Cox regression data for prediction of mortality and appropriate shock (unadjusted and adjusted for base model) are shown, giving insights into the basic statistical data before multivariate analyses.

1. Data {#s0015}
=======

The data article features supplementary figures and tables related to [@bib1]. See the abstract above for further details describing the data.

2. Experimental design, materials and methods {#s0020}
=============================================

A prospective international clinical study was initiated as part of the European Union Seventh Framework funded large-scale cooperative project EUTrigTreat. The rationale, objectives and design of the study including statistical plan and sample size calculations have been published previously. In brief, the study enrolled a contemporary implantable cardioverter defibrillator cohort to test multiple carefully selected risk markers of clinical relevance for prediction of mortality and arrhythmias. The large majority of patients underwent non-invasive programmed ventricular stimulation via their implanted ICDs. Inducibility of sustained ventricular arrhythmia was defined as induction of a single monomorphic ventricular tachycardia lasting for 30 seconds or two polymorphic ventricular tachycardia/ventricular fibrillation episodes requiring cardioversion. A 24-h Holter monitoring was performed using standard devices. The primary endpoint was all-cause mortality. First appropriate implantable cardioverter defibrillator shock was selected as a key secondary endpoint. Cox regression analysis was implemented as described. Risk models for shock and mortality were developed using forward selection among a set of known potential risk factors ( [Figs. 1](#f0005){ref-type="fig"} and [2](#f0010){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}).Fig. 1CONSORT graph for patient enrolment, patients not considered for final analysis and clinical endpoints.Fig. 1Fig. 2Correlation scatter plot for calculated risk score values of appropriate shock vs. calculated risk score value for mortality (*r* = 0.56, *p* \< 0.001) Horizontal and vertical lines depict the low, intermediate, and high risk values of each score. The figure shows that the correlation is at best moderate despite mathematical significance. Thus, all-cause mortality risk does not coincide well with appropriate shock risk. Individually, a low risk of appropriate shock does occur with a high competing risk of death limiting the effectiveness of implantable cardioverter defibrillator therapy in a given patient (lower right quadrant). Vice versa, individual patients can be identified with fairly high risks of appropriate shock and concomitant moderate risks of death (upper left quadrant). These individuals are expected to have a higher life-prolonging effect of their implantable cardioverter defibrillator therapy, i.e. higher implantable cardioverter defibrillator benefit. The original score values are attached in a table (csv file).Fig. 2Table 1Results for univariate Cox regression for prediction of mortality (unadjusted and adjusted for base model).Table 1**VariablePatientsunadjustedadjusted*****p*****HRCI*****p*****HRCI**Age (per 10 years)635\< 0.00012.201.79-1.2,71LVEF (per 5%)635\< 0.00010.740.68--0.81NYHA \> 2635\< 0.00012.651.82--3.86eGFR (per 30 ml/min)623\< 0.00010.450.35--0.58Male gender6350.07491.600.93--2.76Ischemic vs. non-ischemic6340.03301.731.04--2.22Secondary prevention6340.02110.610.40--0.94History of AF622\< 0.00014.022.56--6.31COPD6350.00012.781.75--4.55NTproBNP/BNP (per 100 ng/l)5820.00161.461.23--1.730.01551.461.16--1.84hs-CRP (per 10 mg/dl)4770.00131.621.29--2.05ICD chambers (dual vs. CRT; single vs. others)635\< 0.00010.62; 1.990.37--1.02; 1.30--3.050.03460.55; 1.000.32--0.91; 0.64--1.56Intrinsic QRS (per 10 ms)5350.00071.131.05--1.200.36501.040.96--1.12Intrinsic QT interval (per 10 ms)5350.4331.020.98--1.060.39600.980.94--1.03Intrinsic QTc interval (per 10 ms)5350.03621.051.005--1.100.90001.000.95--1.05Inducibility on EP testing6160.42801.210.76--1.930.99001.000.61--1.63MTWA (A rules)4930.01251.821.13--2.930.90201.030.63--1.70MTWA (B rules)4930.01131.821.14--2.900.82401.060.65--1.72Holter mean heart rate (per 10 bpm)6340.19301.140.94--1.390.07801.210.98--1.49Holter PVC/24 h (per 100/24 h)6320.65801.001.00--1.000.86401.001.00--1.00Holter nsVT/24 h6320.16400.980.94--1.020.37100.980.95--1.03Holter SDNN (per 10 ms)4700.00750.920.86--0.980.79000.990.92--1.06Holter RMSSD (per ms)4730.69800.830.31--2.220.74500.850.31--2.32Holter DC (per ms)4740.00220.960.94--0.980.24500.980.95--1.01Holter HRT category (TO/TS abnormal)434\< 0.00013.952.06--7.570.0362.051.00--4.17Holter HRT onset (%)4340.00121.181.08--1.280.0741.121.00--1.25Holter HRT slope (ms/RR-interval)4340.00010.880.81--0.950.2820.960.90--1.04[^1]Table 2Results of univariate Cox regression for prediction of appropriate shock (unadjusted and adjusted for base model).Table 2**Variable*****n*****unadjustedadjusted*****p*****HRCI*****p*****HRCI**Age (per 10 years)6350.69700.970.98--1.01LVEF (per 5%)6350.00040.870.80--0.94NYHA \> 26350.50600.860.54--1.36eGFR (per 30 ml/min)6230.01100.720.55--0.93Male gender6350.41401.240.73--2.12Secondary prevention6340.00511.781.19--2.66Ischemic vs. non-ischemic6330.20401.300.87--1.95COPD6350.01302.291.26--4.16History of AF6220.76401.230.68--1.820.4871.170.75--1.83NTproBNP/BNP (per 100 ng/l)5820.33501.200.88--1.630.8951.030.65--1.64hs-CRP (per 10 mg/dl)4770.67100.900.53--1.51ICD chambers (dual vs. CRT, single vs. other)6350.88801.12; 1.030.71--1.75; 0.60--1.780.75901.17; 1.170.74--1.86; 0.66--2.11Intrinsic QRS (per 10 ms)5350.03061.081.01--1.150.11401.060.99--1.14Intrinsic QT (per 10 ms)5350.07361.041.00--1.080.11101.040.99--1.14Intrinsic QTc (per 10 ms)5350.02081.061.00--1.110.08861.050.99--1.10EP inducibility6160.00092.151.40--3.300.01011.841.18--2.89MTWA (A rules)4930.00681.851.18--2.920.05921.580.98--2.56MTWA (B rules)4930.01521.731.11--2.690.11001.460.92--2.32Holter mean heart rate (per 10 bpm)6340.19900.870.70--1.080.15800.850.68--1.07Holter PVCs/24 h (per 100/24 h)6350.28801.001.00--1.000.2811.001.00--1.00Holter nsVT/24 h6350.98701.000.99--1.010.91201.000.98--1.01Holter SDNN (per 10 ms)4700.68501.010.96--1.070.43101.030.96--1.09Holter RMSSD (per ms)4730.91101.000.99--1.010.92401.000.99--1.01Holter DC (per ms)4740.08960.970.95--1.000.21400.980.95--1.01Holter HRT category (TO or TS abnormal, TO/TS abnormal)4340.26101.52; 1.490.87--2.64; 0.78--2.850.25801.60; 1.600.87--2.93; 0.78--3.30Holter HRT onset (%)4340.44701.040.94--1.160.72301.020.91--1.15Holter HRT slope (ms/RR-interval)4340.26400.970.92--1.020.37900.970.91--1.04[^2]Table 3Risk scores for risk of all-cause mortality and risk of appropriate ICD shock.Table 3Mortality score:**0.0547 × age − 0.0452 × lvef + 0.548 \* nyha -- 0.0117 \* egfr + 0.527 × afib + 0.0000376 × ntprobnp**  *Shock score:***− 0.0268 × lvef − 0.00883 × egfr + 0.684 × prevention + 0.619 × inducibility**[^3]

Transparency document. Supplementary material {#s0035}
=============================================
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Transparency data associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2018.11.025>.

[^1]: (Open field = no adjusted value available, AF = atrial fibrillation, CI = confidence interval, COPD = chronic obstructive pulmonary disease, eGFR = estimated glomerular filtration rate, DC = deceleration capacity, HR = hazard ratio, HRT = heart rate turbulence, hs-CRP = high-sensitivity C-reactive protein, ICD = implantable cardioverter defibrillator, EP = electrophysiological, LVEF = left ventricular ejection fraction, MTWA = microvolt T-wave alternans, PVC = premature ventricular contraction, nsVT = non-sustained ventricular tachycardia, NT-pro-BNP = n-terminal-pro-brain natriuretic peptide, NYHA = New York Heart Association functional class, SDNN = standard deviation of RR intervals, RMSSD = mean square root of mean of squared differences between normal-to-normal RR intervals, TO = turbulence onset, TS = turbulence slope).

[^2]: (Open field = no adjusted value available, AF = atrial fibrillation, CI = confidence interval, COPD = chronic obstructive pulmonary disease, eGFR = estimated glomerular filtration rate, DC = deceleration capacity, HR = hazard ratio, HRT = heart rate turbulence, hs-CRP = high-sensitivity C-reactive protein, ICD = implantable cardioverter defibrillator, EP = electrophysiological, LVEF = left ventricular ejection fraction, MTWA = microvolt T-wave alternans, PVC = premature ventricular contraction, nsVT = non-sustained ventricular tachycardia, NT-pro-BNP = n-terminal-pro-brain natriuretic peptide, NYHA = New York Heart Association functional class, SDNN = standard deviation of RR intervals, RMSSD = mean square root of mean of squared differences between normal-to-normal RR intervals, TO = turbulence onset, TS = turbulence slope).

[^3]: age = age in years; lvef = left ventricular ejection fraction in %; egfr = estimated glomerular filtration rate in ml/min; afib = (1 if present in history, 0 if absent); ntprobnp = NT-pro BNP in ng/l; prevention = (1 if secondary prevention indication, 0 if primary prevention indication); inducibility = (1 if inducible arrhythmia in electrophysiologic study, 0 if arrhythmia not inducible)
